FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 02:04:07 17/05/2024 pm IST | ||
| 2.11 EUR / 2.17 EUR | +1.90% |
|
| Current month | -30.69% | ||
| 1 month | -31.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 2.1 | -2.33% |
| 15/24/15 | 2.15 | -6.52% |
| 14/24/14 | 2.3 | +0.44% |
| 13/24/13 | 2.29 | -5.37% |
| 10/24/10 | 2.42 | -2.02% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 01:13 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2J1W |
| ISIN | DE000JK2J1W5 |
| Date issued | 23/02/2024 |
| Strike | 587.5 $ |
| Maturity | Unlimited |
| Parity | 66.03 : 1 |
| Emission price | 2.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.15 € |
|---|---|
| Lowest since issue | 2.1 € |
| Spread | 0.06 € |
| Spread % | 2.78% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
440.6
USD
Average target price
462.6
USD
Spread / Average Target
+4.97%
- Stock Market
- Certificates
- Certificat
